MOTS-c Cycle: Schedules, and the Maths Beneath

A schedule states a duration and a frequency. Multiply them and you get a count of withdrawals, which is the only number the vial cares about. Eight weeks at three withdrawals a week is 24 withdrawals. Twelve weeks at two a week is also 24. Two schedules that sound very different make identical demands on the material.

Turn it around and the count sets the mass. A 10 mg vial supplies 24 withdrawals of 400 mcg only if 24 times 0.4 mg, which is 9.6 mg, fits inside it. It does, with 0.4 mg to spare, and that spare is the part that stays in the barrel, the needle and the residual volume of the vial. The schedule fits on paper and is tighter than it looks in glass.

The most common mistake in reading a vial is treating a higher fill volume as more product. It is not. Concentration is labelled mass divided by added volume, so the fill volume decides how thin the liquid is and nothing else.

The last column is the point of the table. It never moves. Ten milligrams of labelled material stays ten milligrams whether it is spread through 1 mL or 5 mL, and the extra draws in the lower rows are smaller draws, not extra peptide.

Fix the mass instead of the volume and the arithmetic inverts neatly. For a 400 mcg target, the volume needed is 0.4 mg divided by the concentration: at 10 mg per mL that is 0.04 mL, or 4 units; at 5 mg per mL, 0.08 mL, or 8 units; at 2.5 mg per mL, 0.16 mL, or 16 units; at 2 mg per mL, 0.2 mL, or 20 units. Four different syringe readings, one identical mass. And the vial yields 10 divided by 0.4, which is 25 withdrawals of that size, at every one of those concentrations.

That last result is the useful one. Dilution changes what you read on the barrel. It does not change how far a vial goes, once the target is stated as a mass.

A sealed vial of lyophilised powder and a reconstituted vial of solution are different storage problems. The moment water goes in, a second clock starts, and it is indifferent to the schedule written on paper.

Twenty-five withdrawals at one a day is 25 days in solution for the last of them. At three a week it is more than eight weeks, and the final draw comes from liquid that has been sitting, warming slightly each time the vial is handled, since the first. Nothing in the concentration arithmetic accounts for that. Concentration assumes the mass is still there and still intact, which is an assumption about chemistry, not a result of division.

The practical consequence is that a fill volume is also a decision about how long a vial stays open. A smaller fill volume, drawn in larger fractions, empties the vial sooner. A larger fill volume stretches the same mass over more calendar time in liquid form. Neither is automatically right. Both are choices worth making on purpose.

Cycling as a concept arrived from a different pharmacology, where breaks between periods of use have a stated rationale: a suppressed axis that needs to recover, or a receptor population that changes with continuous exposure. Those rationales are specific to the compounds they were worked out for. They are not a general property of injectable substances, and carrying the vocabulary across does not carry the reasoning with it.

For this compound no such rationale has been established in people, because no human efficacy trial has been run. A break of four weeks after eight is not a finding. It is a habit borrowed from a neighbouring hobby.

Cost is the one thing a cycle length reliably determines. Cost per mg is price divided by labelled mass, so a 10 mg vial at 90 currency units is 9 per mg, using an assumed price since none is quoted here. Twenty-five withdrawals of 400 mcg from that vial works out at 90 divided by 25, or 3.60 each. A longer schedule at the same withdrawal size does not change the cost per withdrawal. It changes how many vials the schedule consumes, which is a budgeting fact and not a biological one.

This page names no amount for a person, no frequency, no duration and no starting point. That is not caution for its own sake. It is that the arithmetic on this page cannot produce such a figure, and nothing else on the record can either.

The efficacy work on this compound is animal and cell work. Reported effects on glucose handling and insulin sensitivity come from studies in mice and in cultured cells, and those studies specify amounts per kilogram of animal body weight in defined models. Multiplying such a figure by a person's weight is easy and produces a number with nothing behind it, because clearance and route do not carry across species.

Nor can the registry supply one, though at a glance it looks as though it might. NCT07505745 is listed as a Phase 2 study of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity, enrolment 120, status recruiting. Its lead sponsor, Hudson Biotech, holds eight such entries posted between February and April 2026, covering seven other compounds sold in this market alongside this one, all recruiting at a single site, and one of them states in its own brief summary that it is a fictional example of a ClinicalTrials.gov-style record. The further hits on that search are unrelated studies matched on text rather than on intervention.

So there is no registered human trial of MOTS-c: no schedule to wait for, and no protocol document to copy a duration from. The animal and cell literature is real, and the founding paper is Lee and colleagues in Cell Metabolism, 2015. It reports exposure windows chosen to suit an experiment in mice, which is not a recommendation and does not convert.

The compound holds no marketing authorisation from any regulator and is sold as a research chemical, which means the labelled mass at the top of every calculation here is a seller's claim rather than a verified assay. All of this arithmetic is exact given an accurate label, and inherits the label's error when it is wrong.